Aprea Therapeutics AB has appointed Eyal Attar as chief medical officer to help drive the development of its anticancer therapies targeting the p53 tumour suppressor protein. Dr Attar, a physician trained in medical haematology and oncology, joins Aprea from Agios Pharmaceuticals Inc where he was senior medical director. Prior to this, he was on the clinical staff at the Massachusetts General Hospital Cancer Center where he was a member of the Center for Leukemia and assistant professor of medicine at Harvard Medical School. Dr Attar received his medical degree from the University of North Carolina School of Medicine. He brings nearly 20 years of medical research and clinical development experience to Aprea which is co-located in Boston, US and Stockholm, Sweden.
Aprea Therapeutics announced the appointment on 25 March 2019.
Copyright 2019 Evernow Publishing